PETRI DISH PERSPECTIVES
Burma | Chicago
Scientist 🥼🧪🔬
Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎
Stream new episodes every THURSDAY!
https://linktr.ee/maneadkhin
#biotech #pharma #healthcare #podcast #petridishperspectives
Episodes
71 episodes
Episode 63: Enveda Biosciences
In this episode of Petri Dish Perspectives, we explore the story of Enveda Biosciences, one of the most exciting AI-native biotech companies redefining how drugs are discovered. While most pharmaceutical companies build vast syn...
Episode 62: Isomorphic Labs
In this episode of Petri Dish Perspectives, we explore the story of Isomorphic Labs, Alphabet's ambitious drug discovery company born out of DeepMind's groundbreaking work on AlphaFold. From solving one of biology's greatest mys...
June 2026: Biotech & Pharma NEWS Roundup
Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026!This month was dominated by a relentless wave of strategic consolidation and "barbell" deal-making, as Big Pharma aggressively swapped ca...
Episode 61: Danaher
In this episode of Petri Dish Perspectives, we explore how two brothers transformed a small industrial holding company into one of the most influential life sciences organizations in history. We dive into the origins of the Danaher Bus...
Episode 60: Hims & Hers
In this episode of Petri Dish Perspectives, we dive into the rise of Hims & Hers Health, the telehealth company that transformed direct-to-consumer healthcare and challenged traditional medicine. Founded in 2017 by Andrew Du...
Episode 59: Illumina
In this episode of Petri Dish Perspectives, we dive into the remarkable story of Illumina, from a small sequencing startup born during the Human Genome Project era to the company that transformed DNA sequencing from a billion-dollar sc...
Episode 58: UnitedHealthcare
In this episode of Petri Dish Perspectives, we dive into the remarkable rise of UnitedHealthcare and its parent company, UnitedHealth Group. From its origins in the 1970s managed care movement to becoming a healthcare empire worth hund...
May 2026: Biotech & Pharma NEWS Roundup
Welcome to your essential overview of the global biotech and pharmaceutical landscape for May 2026!This month was dominated by a wave of aggressive cross-border M&A and strategic capital deployment, as pharma giants pivoted to secure...
Episode 57: 23andMe
This week on Petri Dish Perspectives, we unpack the story of 23andMe, the company that turned saliva kits into one of the largest human genetic databases in the world and brought genomics out of hospitals and into millions of homes.
Episode 56: Thermo Fisher
This week on Petri Dish Perspectives, we’re diving into the story of Thermo Fisher Scientific, the company quietly powering nearly every corner of modern biotechnology.From its origins in scientific instrumentation to becoming a...
Episode 55: Alnylam
From the discovery of RNA interference to the first FDA-approved gene-silencing therapy, this week on Petri Dish Perspectives, we dive into the story of Alnylam Pharmaceuticals, the company that turned one of biology’s most powerful me...
Episode 54: All about 340B
In this episode of Petri Dish Perspectives, we break down the 340B Drug Pricing Program, a little-known but massively influential policy shaping how hospitals, pharmacies, and drug manufacturers operate today. Created under the ...
April 2026: Biotech & Pharma NEWS Roundup
Welcome to your essential overview of the global biotech and pharmaceutical landscape for April 2026!This month was dominated by a high-stakes pivot toward oral obesity treatments, a massive consolidation of precision oncology platforms ...
Episode 53: CAR-T Therapies
What if cancer treatment wasn’t a drug but a living, evolving system inside your body?In this episode, we break down one of the most revolutionary innovations in modern medicine: CAR-T cell therapy. From its origins in academic la...
Episode 52: Daiichi Sankyo
In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down the rise of Daiichi Sankyo, a company that quietly transformed itself from a cardiovascular powerhouse into one of the most dominant players in modern oncolog...
Episode 51: ImmunoGen
In this episode of Petri Dish Perspectives: Biotech Unleashed, we dive into the 40+ year journey of ImmunoGen, a company that refused to give up on one of the most complex and misunderstood technologies in oncology: antibody-drug conju...
Episode 50: Exact Sciences
In this episode of Petri Dish Perspectives, we’re dissecting the "Phoenix of Biotech." On March 23, 2026, the era of Exact Sciences as an independent company officially ended with its massive $23 billion acquisition by Abbott Laboratories. But ...
Episode 49: AI in Pharma / Biotech
In this episode, we explore the high-stakes reality of AI integration in the life sciences. We move past the speculative hype to examine the mechanical necessity of this shift, driven by soaring R&D costs and an explosion of biological data...
March 2026: Biotech & Pharma NEWS Roundup
Welcome to your essential overview of the global biotech and pharmaceutical landscape for March 2026!This month was dominated by by three massive themes: more AI integrations, M&A deals, and continued GLP-1 challenges.🎧 Lis...
Episode 48: Ginkgo Bioworks
In this episode of Petri Dish Perspectives, we unpack how Ginkgo Bioworks set out to industrialize biology. From its origins at MIT to building one of the most ambitious synthetic biology platforms in the world, we explore how the comp...
Episode 47: SUN Pharma
From a small operation built on just ₹10,000 to a global pharmaceutical powerhouse, Sun Pharmaceutical Industries is one of the most compelling growth stories in modern biotech.In this episode of Petri Dish Perspectives: Biote...
Episode 46: Servier
In this episode of Petri Dish Perspectives, we explore the remarkable history of Servier, France’s largest independent pharmaceutical company and one of the only major drugmakers owned by a non-profit foundation. Founded in 1954 by the...
Episode 45: BioMarin
Most biotech companies chase massive markets. But BioMarin Pharmaceutical built its entire strategy around something very different: ultra-rare genetic diseases affecting only small patient populations around the world.In this epi...